Señales en vivo de NBIO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 abr 2024 @ 11:03):

Stats
Volumen de hoy	1 700.00
Volumen promedio	63 766.00
Capitalización de mercado	16.96M
EPS	$0 ( 2024-02-14 )
Próxima fecha de ganancias	( $0 ) 2024-06-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.99
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Holden Lowell Thomas	Buy	112 500	Common Stock
2024-03-31	Carrick Sean	Buy	225 000	Common Stock
2024-03-31	Karas Douglas John	Buy	27 100	Common Stock
2023-12-29	Carrick Sean	Buy	239 300	Common Stock
2023-12-29	Holden Lowell Thomas	Buy	119 650	Common Stock

INSIDER POWER
58.65
Last 100 transactions
Buy: 40 920 261 \| Sell: 7 165 000

Nascent Biotech, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nascent Biotech, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.0236

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.0236

FY	2022
Ingresos:	$1.00M
Beneficio Bruto:	$1.00M (100.00 %)
EPS:	$-0.00140

FY	2021
Ingresos:	$750 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.